Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)

NCT02413138 · clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
TERMINATED
Status
41
Enrollment
INDUSTRY
Sponsor class

Stopped The primary endpoint of non-inferiority to daily therapy in the pediatric Phase 3 study was not achieved

Conditions

Interventions

Sponsor

Versartis Inc.